CTIS2024-514967-25-00进行中（未招募）1 期
PET imaging of tumors with strong desmoplastic reaction in pancreas, bile ducts, ventricle and ovaries by a novel tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor - H035FAPI-PET
Karolinska University Hospital0 个研究点目标入组 410 人开始时间: 2024年6月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 410
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.The subject has given written consent to participate in the study, 2.The subject has suspected pancreatic, gastric, biliary or epithelial ovarian cancer based on multimodal strategy including markers in blood, markers in tissue and imaging diagnostics; scheduled for surgical removal of this lesion with histopathological confirmation of diagnosis.
排除标准
- •Age =18 year, Pregnancy and lactation, Known metastatic disease (Not applicable for the EOC study group as most cases are already metastasized at the point of primary diagnosis), Significantly reduced renal function, Allergy to iodinated contrast media, Subjects that for some reason are unable to exercise their own rights, such as cognitive function impairment
研究者
相似试验
已完成
1 期
A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2MProstate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancerJPRN-UMIN000015356niversity of Tsukuba15
招募中
不适用
[68Ga]Ga-PSMA-11 PET/MR-imaging of malignant intra-axial brain tumors; primary assessment of PSMA expression, optimization of compound delivery and determination of theranostic potential.NL-OMON49568Erasmus MC, Universitair Medisch Centrum Rotterdam25
招募中
不适用
PET/CT Robustness In Melanomamole cancer10040900MelanomaNL-OMON48328Antoni van Leeuwenhoek Ziekenhuis28
尚未招募
不适用
Phase 1 clinical trial for PET image evaluation of [F-18]Florastamin in suspected prostate cancer subjectsDiseases of The genitoruinary systemKCT0004609FutureChem20
撤回
1 期
An imaging study of 64Cu-SARTATE using positron emission tomography in paediatric patients with high-risk neuroblastoma.ACTRN12617001259336Clarity Pharmaceuticals LTD10